drugset / Trial / NCT00275015

Cyclophosphamide and Total Body Irradiation in Treating Patients Who Are Undergoing an Autologous Peripheral Stem Cell Transplant For Chronic Lymphocytic Leukemia

NCT00275015

Phase 2 Completed 169 enrolled German CLL Study Group
NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: Giving chemotherapy before a peripheral stem cell transplant stops the growth of cancer cells by stopping them from dividing or killing them. Giving colony-stimulating factors, such as G-CSF, and certain chemotherapy drugs, helps stem cells move from the bone marrow to the blood so they can be collected and stored. Chemotherapy or radiation therapy is then given to prepare the bone marrow for the stem cell transplant. The stem cells are then returned to the patient to replace the blood-forming cells that were destroyed by the chemotherapy and radiation therapy. PURPOSE: This phase II trial is studying how well giving cyclophosphamide together with total-body irradiation works in treating patients who are undergoing an peripheral stem cell transplant for chronic lymphocytic leukemia.

Timeline

Start
1998-01
Primary completion
Completion
2012-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Cyclophosphamide Other / unclassified 60 mg/kg Intravenous
Subject Cytarabine Small molecule
Subject Dexamethasone Small molecule
Subject Etoposide Small molecule
Subject Fludarabine Small molecule
Subject Melphalan Small molecule
Subject carmustine Small molecule
Subject filgrastim Protein / enzyme biologic